BCYC

Bicycle Therapeutics Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↓ 4/10
  • Value↑ 9/10
Bicycle Therapeutics sales and earnings growth
BCYC Growth
Neutral
  • Revenue Y/Y↑ 145.07%
  • EPS Y/Y↓ -0.32%
  • FCF Y/Y↓ -27.27%
Bicycle Therapeutics gross and profit margin trends
BCYC Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -345.00%
  • ROIC 5Y↓ -395.23%
Bicycle Therapeutics net debt vs free cash flow
BCYC Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -1071.0

Bicycle Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks